CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017
SITGES, Spain — 11 July 2017
Global biotherapeutics leader CSL Behringtoday announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken Leadership Awards. There are two 2017 recipients of this global awards program which provides monetary grants and/or product supply for investigational use to support research focusing on the potential role of immunoglobulin (Ig) therapy in the treatment of neurological/neuromuscular disorders……
This program has awarded over $5 million in grants and study drug over the past seven years for researching Ig therapy in a variety of neurological/neuromuscular disorders including idiopathic inflammatory myositis, neuromyelitis optica, Duchenne muscular dystrophy, complex regional pain syndrome, paraneoplastic syndromes, autoimmune peripheral neuropathies, Guillain-Barré syndrome and neuromuscular junction disorders such as myasthenia gravis and Lambert Eaton Myasthenic Syndrome.
https://www.cslbehring.com/newsroom/2017/20170711-ila-awards
Ann: Antisense Therapeutics transitions to new Board Chair, page-96
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.40M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $102.2K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 142 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341267 | 4 |
View Market Depth
| Last trade - 15.58pm 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |